HTLV prevalence is no longer following the decreasing HIV prevalence - 20 years of retroviral surveillance in Guinea-Bissau, West Africa.


Journal

Acta tropica
ISSN: 1873-6254
Titre abrégé: Acta Trop
Pays: Netherlands
ID NLM: 0370374

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 29 04 2018
revised: 09 02 2019
accepted: 12 02 2019
pubmed: 17 2 2019
medline: 10 4 2019
entrez: 17 2 2019
Statut: ppublish

Résumé

The HIV-2 and HTLV-1 prevalences in Bissau have followed similar trends in surveys from 1996 and 2006 with HTLV-1 prevalences of 3.6% and 2.3%, respectively. However, following the introduction of antiretroviral treatment (ART) and informative campaigns about HIV, the epidemics may have shifted. To evaluate the current HTLV prevalence and the continued association with HIV, we performed a third survey. A cross-sectional survey was performed from November 2014 to February 2016. In total, 2583 participants were interviewed, tested for HIV, and had blood samples collected. Samples were analysed for anti-HTLV using chemiluminescence and immunoblot assays. We calculated the HTLV prevalence for 2016 and examined risk factors for HTLV and associations with HIV using binominal regression. The prevalence of HTLV was 2.8% (71/2583), 1.5% (16/1,089) for men and 3.7% (55/1,494) for women. Old age, female sex, HIV-2 infection and sharing a house with a HTLV- infected person were strong risk factors for HTLV. In contrast to previous studies, we found a non-significant increase in prevalence among the 15-24 year-olds since 2006, supporting ongoing transmission. The HTLV prevalence in Bissau showed a non-significant increase. We found evidence supporting continuous vertical and horizontal routes of transmissions.

Sections du résumé

BACKGROUND BACKGROUND
The HIV-2 and HTLV-1 prevalences in Bissau have followed similar trends in surveys from 1996 and 2006 with HTLV-1 prevalences of 3.6% and 2.3%, respectively. However, following the introduction of antiretroviral treatment (ART) and informative campaigns about HIV, the epidemics may have shifted. To evaluate the current HTLV prevalence and the continued association with HIV, we performed a third survey.
METHODS METHODS
A cross-sectional survey was performed from November 2014 to February 2016. In total, 2583 participants were interviewed, tested for HIV, and had blood samples collected. Samples were analysed for anti-HTLV using chemiluminescence and immunoblot assays. We calculated the HTLV prevalence for 2016 and examined risk factors for HTLV and associations with HIV using binominal regression.
RESULTS RESULTS
The prevalence of HTLV was 2.8% (71/2583), 1.5% (16/1,089) for men and 3.7% (55/1,494) for women. Old age, female sex, HIV-2 infection and sharing a house with a HTLV- infected person were strong risk factors for HTLV. In contrast to previous studies, we found a non-significant increase in prevalence among the 15-24 year-olds since 2006, supporting ongoing transmission.
CONCLUSIONS CONCLUSIONS
The HTLV prevalence in Bissau showed a non-significant increase. We found evidence supporting continuous vertical and horizontal routes of transmissions.

Identifiants

pubmed: 30771284
pii: S0001-706X(18)30538-2
doi: 10.1016/j.actatropica.2019.02.015
pii:
doi:

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-150

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Mads Mose Jensen (MM)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Clinical Immunology, Aarhus University Hospital, Denmark. Electronic address: Madsmose@gmail.com.

Jens Steen Olesen (JS)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Bertram Kjerulff (B)

Department of Clinical Immunology, Aarhus University Hospital, Denmark.

Stine Byberg (S)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.

Zacarias José da Silva (ZJ)

National Public Health Laboratory, CP 1013, Bissau, Guinea-Bissau.

Amabelia Rodrigues (A)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.

Sanne Jespersen (S)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Christian Wejse (C)

Department of Infectious Diseases, Aarhus University Hospital, Denmark; GloHAU, Center for Global Health, Aarhus University Hospital, School of Public Health, Aarhus, Denmark.

Peter Aaby (P)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.

Christian Erikstrup (C)

Department of Clinical Immunology, Aarhus University Hospital, Denmark.

Bo Langhoff Hønge (BL)

Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Clinical Immunology, Aarhus University Hospital, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH